BofA/Merrill Lynch Starts ProNAi Therapeutics (DNAI) at Buy
Tweet
Share
E-mailGet Alerts DNAI Hot Sheet
Price: $1.56 --0%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 6
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 6
Join SI Premium – FREE
BofA/Merrill Lynch initiated coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $35.00.
For an analyst ratings summary and ratings history on ProNAi Therapeutics click here. For more ratings news on ProNAi Therapeutics click here.
Shares of ProNAi Therapeutics closed at $28.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Bending Spoons (BSP) to Underperform
- BofA Securities: 'INTC well positioned to address $380B CY30 foundry TAM'
- On Holding AG (ONON) PT Lowered to $46 at BofA Securities
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
